We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
"DELFI is tackling one of the most important unmet needs in oncology, and the combination of a differentiated fragmentomics platform, an integrated AI approach, a clear path to FDA approval and broad ...
A new study suggests that a single blood sample could soon detect multiple cancers, including liver, stomach, and lung cancer, and other diseases by measuring the blood for DNA fragments.
A novel low-cost assay sequencing cell-free DNA methylome in blood demonstrates strong performance across a range of clinical applications.
TRIM28-mediated SUMOylation of ERG at K389 and its association with cell proliferation, PARP inhibitor response, and 53BP1 expression in castration-resistant prostate cancer. Heterogeneity and ...
Circulating tumor DNA (ctDNA) can be detected in plasma samples sometimes several years prior to a clinical diagnosis of cancer, according to research ...
Study: Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test. Image Credit: 3dMediSphere / Shutterstock In a recent study published in the ...
Beyond traditional monitoring of kidney transplant recipients, donor derived-cell free DNA may permit early identification of graft damage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results